Menu
Recruiting NCT06629389

Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms

Phase II Interventional Parkinson Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cannabidiol 100 mg/ml, cannabidiol 300 mg/ml, Cannabidiol 400 mg/ml, Placebo.
Who it may be relevant to
Registry conditions: Parkinson Disease. Basic parameters: 40 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Argentina
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Evaluate Safety and Tolerability of Cannabidiol (Kanbis®) for the Treatment of Parkinson's Disease Symptoms

Overview

Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder characterized by clinical motor and non-motor symptoms. Knowing the potential benefits has led to the use of cannabis as an alternative therapy.

Detailed description

To evaluate safety and tolerability of CBD-based drug product at different doses

Interventions

  • Drug Cannabidiol 100 mg/ml
    The following dose regime for the 4 treatment arms will be used: DOSE TITRATION PERIOD: First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The fir
  • Drug cannabidiol 300 mg/ml
    The following dose regime for the 4 treatment arms will be used: DOSE TITRATION PERIOD: First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The fir
  • Drug Cannabidiol 400 mg/ml
    The following dose regime for the 4 treatment arms will be used: DOSE TITRATION PERIOD: First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The fir
  • Drug Placebo
    The following dose regime for the 4 treatment arms will be used: DOSE TITRATION PERIOD: First 5 days: 0.3 mL/day (1 dose) Subsequent 5 days: 0.6 mL/day (2 doses of 0.3 mL/dose) Subsequent 5 days: 0.8 mL/day (2 doses of 0.4 mL/dose) Last 5 days: 1 mL/day (2 doses of 0.4 mL/dose) PERIOD OF ACTIVE TREATMENT Continue with the last dose set by the titration schedule (for 12 weeks). PERIOD OF TREATMENT INTERRUPTION Medication is gradually discontinued every 7 days until complete termination. The fir

Primary outcome measures

  • Number of patients with advers events related to treatment acording to CTCAE v5.0 [Time frame: up to 21 weeks]
Secondary outcome measures (10)
  • Changes in differents motors scales in Parkinson desease [Time frame: up to 15 weeks]
  • Changes in the off periods in Parkinson desease [Time frame: up to 15 weeks]
  • Changes in the patients Clinical Global Impression in Parkinson desease [Time frame: up to 21 weeks]
  • Changes in the quality-of-life in Parkinson desease [Time frame: up to 15 weeks]
  • Changes in differents no motors symproms in Parkinson desease [Time frame: up to 15 weeks]
  • Changes in depression in Parkinson desease [Time frame: up to 15 weeks]
  • Changes in sleep in Parkinson disease [Time frame: up to 15 weeks]
  • Changes in Cognitive Assessment in Parkinson desease [Time frame: up to 15 weeks]
  • Changes in apathy in Parkinson desease [Time frame: up to 15 weeks]
  • Changes in pain in Parkinson desease [Time frame: up to 15 weeks]

Eligibility criteria

Inclusion criteria

  • Participants between 40 and 80 years old.
  • Participants diagnosed with PD according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson\'s disease (72), and to the Brain Bank Criteria for Parkinson\'s disease, with mild to moderate disease as measured by the modified Hoehn and Yahr scale. (Both clinical criteria are included since many of the study participants were diagnosed with previous criteria and others with current criteria, both of which are very similar and do not change or raise any doubt about the diagnosis of the disease).
  • Participants who have not changed their anti-Parkinson's drugs (or dose) at least one month prior to study entry.
  • Acceptance by the participant by signing the ICF.
  • Subjects capable of giving consent to participate in the study

Exclusion criteria

  • Evidence of dementia, Mini-Mental State Exam score less than 24 or with previous diagnosis by cognitive assessment .
  • Severe psychiatric pathology: severe depression, treatment-refractory psychosis. Evaluation by psychiatrist who confirms the pathology. History of hospitalization in a psychiatric center or mental health center is an exclusion criterion regardless of the time spent since hospitalization or the reason for which the patient was hospitalized.
  • Known or suspected allergy to cannabinoids or inactive ingredients used in the formulation of the study drug.
  • History of drug or alcohol dependence.
  • Use of dopamine blockers within 180 days prior to study entry.
  • Use of amphetamine inhibitors, cocaine and MAO-A inhibitors within 90 days prior to study entry.
  • Patients who have received within 90 days prior to study entry the following drugs due to drug interactions: valproic acid, felbamate, niacin (nicotinic acid) at doses ≥2000mg/day or nicotinamide (nicotinic acid amide or nicotinamide) at doses ≥3000mg/day, isoniazid, ketoconazole and/or clobazam.
  • Unstable medical condition detected by the following laboratory alterations: Hemoglobin\<10g/dL, Leukocytes\<4000 u/ml, Neutrophils\<1500 u/ml, Lymphocytes\<500u/ml, Platelets\<100000 u/ml, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\> 3 times the upper limit of normal.
  • Moderate-severe liver disease. (Child Pugh B-C)
  • Pregnant or breastfeeding.
  • Women of reproductive age who do not agree to use at least one contraceptive method of proven efficacy (diaphragm or partner using condom, oral or implanted hormonal contraceptive; intrauterine device, stable partner with vasectomy), until at least four weeks after completion of study treatment. Pregnancy blood test will be performed before starting the study.
  • Participants who have had a surgical procedure for PD, either deep brain stimulation or surgery for lesion.
  • Patients de novo or with recent diagnosis of PD (less than 5 years).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Argentina · 1 center
  • Hospital Español de Mendoza — Mendoza

Identifiers

NCT: NCT06629389 · CBD-EP-2

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗